Clinical Trials Directory

Trials / Conditions / ER+ Breast Cancer

ER+ Breast Cancer

26 registered clinical trials studyying ER+ Breast Cancer — 13 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingEvaluation of Adherence to Cell Cycle Inhibitors Used as Adjuvant Therapy in Patients With Localized Breast Ca
NCT07443774
University Hospital, Grenoble—
RecruitingA Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer
NCT07483307
Memorial Sloan Kettering Cancer CenterPhase 2
RecruitingBreast Re-irradiation After Second Ipsilateral Lumpectomy
NCT06867484
Youssef ZeidanN/A
RecruitingCirculating Tumor DNA
NCT06923527
Yale UniversityPhase 2
RecruitingA Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
NCT07002177
Forward Pharmaceuticals Co., Ltd.Phase 1 / Phase 2
Not Yet RecruitingImprovement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patient
NCT06407401
European Organisation for Research and Treatment of Cancer - EORTCPhase 3
Active Not RecruitingTrial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer
NCT06590857
RayzeBio, Inc.Phase 1 / Phase 2
RecruitingBreast Cancer Evolution During Neoadjuvant Systemic Therapy
NCT06681064
Royal Marsden NHS Foundation Trust—
RecruitingA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519
858 Therapeutics, Inc.Phase 1 / Phase 2
Active Not RecruitingStudy of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subj
NCT05827614
Boundless Bio, Inc.Phase 1
Active Not RecruitingFulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Su
NCT04920708
Royal Marsden NHS Foundation TrustPhase 2
RecruitingJAB-2485 Activity in Adult Patients With Advanced Solid Tumors
NCT05490472
Jacobio Pharmaceuticals Co., Ltd.Phase 1 / Phase 2
UnknownTamoxifen Prediction Study in Patients With ER+ Breast Cancer
NCT05525481
Erasmus Medical CenterPhase 4
RecruitingA Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Trea
NCT05534438
Memorial Sloan Kettering Cancer CenterPhase 2
CompletedAlcohol and Breast Cancer (ABC) Trial
NCT05423730
Beth Israel Deaconess Medical CenterN/A
RecruitingA Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palboc
NCT04985266
Royal Marsden NHS Foundation TrustPhase 2
Active Not RecruitingNeoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the
NCT04551495
Jules Bordet InstitutePhase 2
Unknown4FMFES-PET Imaging of ER+ Advanced Breast Cancers
NCT04824014
Centre de recherche du Centre hospitalier universitaire de SherbrookePhase 2
RecruitingFES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
NCT04174352
University of Wisconsin, MadisonEARLY_Phase 1
RecruitingPAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
NCT04360941
Royal Marsden NHS Foundation TrustPhase 1
Active Not RecruitingNaptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid T
NCT03983954
NeoTX Therapeutics Ltd.Phase 1
CompletedTamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxif
NCT04312347
Nalagenetics Pte LtdN/A
CompletedCYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)
NCT02580448
Innocrin PharmaceuticalPhase 1 / Phase 2
CompletedSafety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Pati
NCT01202591
AstraZenecaPhase 1 / Phase 2
CompletedStudy of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in
NCT00828854
Syndax PharmaceuticalsPhase 2
CompletedStudy to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With
NCT00676663
Syndax PharmaceuticalsPhase 2